["Precision oncology": not yet ready for prime time?]
Les limites de l’ « oncologie de précision » - Chroniques génomiques.
Journal
Medecine sciences : M/S
ISSN: 1958-5381
Titre abrégé: Med Sci (Paris)
Pays: France
ID NLM: 8710980
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
entrez:
18
12
2019
pubmed:
18
12
2019
medline:
12
6
2020
Statut:
ppublish
Résumé
The concept of precision oncology is straightforward, but the actual results of treating advanced cancer patients with the targeted drug suggested by genomic analysis have been generally disappointing, indicating that this approach is not yet ready for routine clinical practice. A number of possible improvements can and will be tested by additional clinical trials.
Identifiants
pubmed: 31845885
doi: 10.1051/medsci/2019177
pii: msc190256
doi:
Types de publication
Journal Article
Langues
fre
Sous-ensembles de citation
IM
Pagination
905-907Informations de copyright
© 2019 médecine/sciences – Inserm.
Références
Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol 2013 ; 31 : 1803–5.
Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol 2013 ; 31 : 1806–14.
Mendelsohn J. Personalizing oncology: perspectives and prospects. J Clin Oncol 2013 ; 31 : 1904–11.
Le Tourneau C, Delord JP, Gonçalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015 ; 16 : 1324–34.
Trédan O, Wang Q, Pissaloux D, et al. Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial. Ann Oncol 2019 ; 30 : 757–65.
Billaud M, Guchet X. L’invention de la médecine personnalisée : entre mutations technologiques et utopie. Med Sci (Paris) 2015 ; 31 : 797–803.
Tannock IF, Hickman JA. Molecular screening to select therapy for advanced cancer? Ann Oncol 2019 ; 30 : 661–3.
Jordan B. Hétérogénéité des tumeurs : l’apport du séquençage sur cellules individuelles. Med Sci (Paris) 2014 ; 30:1184–6.
Lin A, Giuliano CJ, Palladino A, et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med 2019 ; 11. pii: eaaw8412.
Jordan B. L’invasion des tests non-invasifs. Med Sci (Paris) 2014 ; 30 : 107–8.
Mattox AK, Bettegowda C, Zhou S, et al. Applications of liquid biopsies for cancer. Sci Transl Med 2019 ; 11. Pii: eaay1984.